| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_226039ec87416be431e9ecc4059fb764
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95474295176222713f1e8864e40a36da |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2011-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_838a1ab42a99b76c509aa5985538015d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9f3be20ab692a68cb785d280b423937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7da3b1ac0f1ac4b164dc024366e64028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3121e4febd92315d3e958bba630f1358 |
| publicationDate |
2015-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2011291450-B2 |
| titleOfInvention |
TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease |
| abstract |
Methods, compositions and kits based on TAM receptors, or TAM receptor ligands or agonists are provided for detection of neuropathological diseases or determination of their progression. The neural diseases in particular include multiple schlerosis or other inflammatory neural disorders that are characterized by demyelination, oligodendrocyte cytotoxicity and microglial activation. These methods include screening cells of a subject where identification of an elevation of expression of a TAM receptor or a change in expression of a TAM receptor ligand is diagnostic of the disease presence or progression. In addition treatment of subjects with such neuropathological diseases by administering TAM receptor ligands (such as GAS 6 or Protein S) or by administering agonists such as antibodies specific for the TAM receptors; Axl, Mer or Tyro3 is described. |
| priorityDate |
2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |